The companies seek to track adherence for self-administered drug therapies, including biologics. They plan to integrate France-based Biocorp’s Injay technology with BD’s UltraSafe Plus passive needle guard.
Biocorp designed Injay to capture and transmit injection events using near-field communication (NFC) technology. BD developed its UltraSafe Plus passive needle guard for use with pre-fillable syringes.
More about the partnership between Biocorp and BD
Injay monitors the use of pre-fillable syringes in clinical studies or routine care. It can confirm a complete injection and transfer that information to a smartphone with NFC technology and specific sensors.
“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence,” said Matthew Schabacker, VP and GM of advanced drug delivery solutions at BD. “Our agreement with BioCorp enables us to explore innovative solutions in this market and further supports BD’s commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes — as we combine Biocorp’s expertise in developing and commercializing connected drug delivery devices to our existing portfolio of advanced injection drug delivery systems.”
BD said there is an increased prevalence of self-administered therapies for chronic diseases. It also pointed to the “pervasiveness” of digital technologies in everyday life. The two companies joined forces because of the opportunities to improve outcomes and increase medication adherence monitoring capabilities..
“We are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market,” said Eric Dessertenne, CEO of Biocorp. “It shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.”